Tourage Soleimani, MD
Cardiovascular Disease · Los Angeles, CANPI 1174573588
Payments from drug & device makers
Across 423 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Novartis$1K
- Amgen$1K
- Johnson & Johnson$975
- AstraZeneca$660
- Pfizer$549
- plus $2K from 25 others
What the payments were for
- Food & beverage$8,19499%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 63 | $1,398 |
| Novartis | 73 | $1,259 |
| Amgen | 47 | $1,077 |
| Johnson & Johnson | 45 | $975 |
| AstraZeneca | 37 | $660 |
| Pfizer | 32 | $549 |
| E.r. Squibb & Sons, L.L.C. | 38 | $504 |
| Amarin Pharma, Inc. | 17 | $284 |
| Bayer | 10 | $209 |
| Edwards Lifesciences | 8 | $186 |
| Merck | 8 | $164 |
| Abbott | 7 | $141 |
| Boston Scientific | 5 | $122 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $108 |
| Novo Nordisk | 5 | $101 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 2 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| AbbVie(2 entities) | 2 | $40 |
| Bridgebio Pharma, Inc. | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $27 |
| Heartflow, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| Biotronik Inc. | 1 | $25 |
| Medtronic | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Preventice Services, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
How this compares
$8,240 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $281,000 |
| Repatha SureclickEvolocumab | 136 | $101,697 |
| OzempicSemaglutide | 83 | $94,175 |
| EntrestoSacubitril/Valsartan | 61 | $63,620 |
| XareltoRivaroxaban | 64 | $63,383 |
| MounjaroTirzepatide | 43 | $58,831 |
| JardianceEmpagliflozin | 41 | $35,299 |
| VascepaIcosapent Ethyl | 80 | $31,194 |
| FarxigaDapagliflozin Propanediol | 25 | $30,566 |
| JanuviaSitagliptin Phosphate | 15 | $21,336 |
| LinzessLinaclotide | 31 | $18,910 |
| Repatha SyringeEvolocumab | 16 | $16,665 |
| LivaloPitavastatin Calcium | 24 | $14,721 |
| BrilintaTicagrelor | 25 | $14,696 |
| MyrbetriqMirabegron | 11 | $12,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $549 | $281,000269 claims |
| Novo NordiskOzempic | $101 | $94,17583 claims |
| NovartisEntresto | $1,259 | $63,62061 claims |
| Johnson & JohnsonXarelto | $975 | $63,38364 claims |
| Lilly USA, LLCMounjaro | $18 | $58,83143 claims |
| AstraZenecaFarxiga, Brilinta, Crestor | $660 | $57,35379 claims |
| Boehringer IngelheimJardiance | $1,398 | $35,29941 claims |
| MerckJanuvia, Janumet | $164 | $30,80029 claims |
| AbbVieLinzess, Creon, Synthroid | $40 | $28,60970 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $58 | $14,72124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Kalyanam ShivkumarLos Angeles$2.9M
- Priscilla HsueLos Angeles$2.3M
- Cathleen Bairey-MerzLos Angeles$1.4M
- Somjot BrarLos Angeles$1.2M
- Freny ModyLos Angeles$960K
- Jamil AboulhosnLos Angeles$683K
- Parveen GargLos Angeles$653K
- Karol WatsonLos Angeles$553K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.